

- 9 -

Serial No.: 08/785,455
Group Art Unit No.: 1652

REMARKS

This Supplemental Amendment is believed to place the subject application in better condition for allowance. Entry of this Amendment and reconsideration of the subject application in view thereof are respectfully requested.

Claims

Claims 26-55 were pending in the application

Claims 27-45 and 55 have been canceled without prejudice or disclaimer of the subject matter therein. Moreover, the applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

New claims 56-91, directed to Group I, have been added. Any amendments made herein to the claims were made to solely expedite or otherwise facilitate prosecution and were not made nor should they be construed to have been made to overcome any issue of unpatentability of the claims as they existed prior to such amendments.

It is not believed that entry of this Amendment will require payment of any additional claim fees. Notwithstanding, Applicant hereby authorizes the Commissioner to charge any claim fees required by entry of this Amendment to Deposit Account No. 50-0258

Support

Support for the amendments is either apparent, or is as described in the text below. The recitals of sequence relatedness, such as the recital "a . . . sequence having at least 30 [50] sequential bases of the polynucleotide sequence set forth in SEQ ID NO:1," finds support at page 15, lines 23-25. The recital of sequence relatedness, such as the recital "a portion of SEQ ID NO:2 containing at least 30 [50] amino acids," finds support at page 11, lines 17-26. Support for the recital "wherein the polypeptide sequence is capable of generating antibodies having binding specificity for the amino acid sequence set forth in SEQ ID NO:2," may be found in the specification at, for example, page 28, lines 7-8 and page 19, line 25 through page 20, line 16. The recital "a second sequence which is identical to the first sequence [SEQ ID NO:2] except that

- 10 -

Serial No.: 08/785,455
Group Art Unit No.: 1652

the second sequence has one [1-5] [5-10] mutation[s] relative to the first sequence, wherein the [each] mutation is a substitution, deletion or insertion of one amino acid," finds support in the specification at, for example, page 14, lines 12-17. The recital of hybridization conditions finds support in the specification at page 15, lines 4-8. No new matter is added.

Claim Rejections

Solely to expedite prosecution and in no way conceding the validity of the rejections to the prior claims, Applicant has elected to present the invention in new terms, which terms obviate the asserted bases for the rejections to the prior claims. Reconsideration and allowance of the subject application are respectfully requested.

Closing Remarks

Applicant thanks the Examiner for the telephonic interview and believes this response will place the application in condition for allowance. Accordingly, favorable reexamination, reconsideration in view of this response and allowance of the pending claims are earnestly solicited.

Respectfully submitted,



Thomas S. Deibert
Registration No. 40,984
for
Allen Bloom
Registration No. 29,135
Attorney for Applicants

Date: March 1, 1999

DECHERT PRICE & RHOADS
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
Fax: (609) 620-3259
Attn: Allen Bloom, Esq.
(609 620-3214)
Thomas S. Deibert, Esq.
(609 620-3231)